Floatz logo

LENVATINIB

Radiotherapy Side Effect

Jian ChenSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Radiotherapy Side Effect cohort.

Asset / SponsorPhaseRating
Rivoceranib
Jian Chen
Phase 2CCC
rafutrombopag
Sir Run Run Shaw Hospital
Phase 2CCC
Sorafenib
Jian Chen
Phase 2CCC
Monosialotetrahexosylganglioside
Sun Yat-sen University
Phase 3CCC
Olaparib
Institut Curie
Phase 1CC

Same molecule, other indications

LENVATINIB is also rated in:

Primary Peritoneal Cavity CancerDormant
BBB
Indicative ·
73 / 100
View asset →
Stage IIB Breast CancerDormant
BBB
Indicative ·
73 / 100
View asset →
portal vein thrombosisDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →